These three patents served as the basis for the development of the Ristenza® formulation. You can access them through the links below.
Below are third party studies done on Ristenza® API’s.
- On-demand use of tramadol, sildenafil, paroxetine and local anesthetics for the management of premature ejaculation: A randomized placebo-controlled clinical trial: (https://pubmed.ncbi.nlm.nih.gov/26558110/)
- Tramadol Use in Premature Ejaculation: Daily Versus Sporadic Treatment: (https://pmc.ncbi.nlm.nih.gov/articles/l)
- Pharmacotherapy of premature ejaculation: a systematic review and network meta-analysis: (https://pubmed.ncbi.nlm.nih.gov/30225547)
- Phosphodiesterase Type 5 Inhibitors for Premature Ejaculation: A Systematic Review and meta-analysis: (https://pubmed.ncbi.nlm.nih.gov/28720356)
- Efficacy and safety of phosphodiesterase type 5 inhibitors on primary premature ejaculation in men: (https://pubmed.ncbi.nlm.nih.gov/26791333/)
- Tramadol for the Management of Premature Ejaculation: (https://www.nature.com/articles/ijir20157)
- Safety and Efficacy of Tramadol Hydrochloride on Treatment of Premature Ejaculation: (https://pmc.ncbi.nlm.nih.gov/articles/PMC3739134/)
- The Use of Tramadol “On-demand” for Premature Ejaculation: A Systematic Review: (https://www.goldjournal.net/article/S0090-4295(12)00980-6/abstract)
- On-demand Tramadol Hydrochloride Use in Premature Ejaculation Treatment: (https://www.sciencedirect.com/science/article/abs/pii/S0090429511024459)
- Tramadol is an Effective Therapy for Mild to Severe Premature Ejaculation: (https://www.nature.com/articles/nrurol.2011.138)
